

## Supplementary Online Content

Leapman MS, Wang R, Park H, et al. Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening. *JAMA Oncol*. Published online November 11, 2021.  
doi:10.1001/jamaoncol.2021.5143

**eTable.** Results of Sensitivity Interrupted Time Series Analysis of Changes in Rates of PSA Testing Relative to Publication of USPSTF Draft Statement on PSA Testing for Prostate Cancer Among Patients Without Evidence of PSA Testing the Preceding 12-Month Period

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable.** Results of Sensitivity Interrupted Time Series Analysis of Changes in Rates of PSA Testing Relative to Publication of USPSTF Draft Statement on PSA Testing for Prostate Cancer Among Patients Without Evidence of PSA Testing the Preceding 12-Month Period

<b>Variable</b>	<b>Estimate</b>	<b>Standard Error</b>	<b>P value</b>
<b>Age 40-89</b>			
Intercept	27.0	0.34	<0.001
Time (bimonthly)	-0.10	0.02	<0.001
Guideline	0.68	0.55	0.23
Additional bimonthly period post-draft guideline	0.24	0.05	<0.001
<b>Age 40-54</b>			
Intercept	19.0	0.29	<0.001
Time (bimonthly)	-0.08	0.02	<0.001
Guideline	0.74	0.46	0.11
Additional bimonthly period post-draft guideline	0.12	0.04	0.01
<b>Age 55-69</b>			
Intercept	42.7	0.55	<0.001
Time (bimonthly)	-0.09	0.04	0.02
Guideline	1.57	0.89	0.08
Additional bimonthly period post-draft guideline	0.29	0.08	0.001
<b>Age 70-89</b>			
Intercept	24.9	0.48	<0.001
Time (bimonthly)	-0.18	0.03	<0.001
Guideline	-0.74	0.07	0.34
Additional bimonthly period post-draft guideline	0.65	0.14	<0.001